辅助性氯胺酮在重度酒精戒断管理中的应用
该回顾性观察性队列研究纳入了63例ICU中按DSM-V标准诊断酒精戒断性谵妄的患者,比较指南实施前(29例)与实施后(34例)在症状触发式苯二氮䓬类和/或苯巴比妥治疗基础上加用氯胺酮持续输注(0.15-0.3 mg/kg/hr,部分患者先给0.3 mg/kg负荷)的结局。结果显示,氯胺酮组插管几率更低(OR 0.14, 95%CI 0.04-0.49, p<0.01),ICU停留缩短2.83天(95%CI -5.58至-0.089, p=0.043),住院时间有缩短趋势但未达统计学显著(减少3.66天, 95%CI -8.40至1.08, p=0.13)。作者认为氯胺酮可能通过拮抗N-甲基-D-天冬氨酸受体减少GABA激动剂镇静需求,从而降低相关并发症。
要点
- 氯胺酮组插管几率显著低于非氯胺酮组(OR 0.14, 95%CI 0.04-0.49, p<0.01)。
- 氯胺酮组ICU停留时间较非氯胺酮组缩短2.83天(95%CI -5.58至-0.089, p=0.043)。
- 氯胺酮组住院时间有缩短趋势但未达统计学显著(减少3.66天, 95%CI -8.40至1.08, p=0.13)。
- 氯胺酮用法为IV持续输注0.15-0.3 mg/kg/hr至谵妄缓解,部分患者先给0.3 mg/kg负荷。
- 所有患者均接受症状触发式苯二氮䓬类和/或苯巴比妥治疗。
适用人群与场景
- 入住ICU并按DSM-V标准诊断为酒精戒断性谵妄(delirium tremens)的患者。
诊断标准与关键阈值
- 酒精戒断性谵妄的诊断依据DSM-V标准。
处置流程与药物剂量
- 所有患者均采用症状触发式给药方式,使用苯二氮䓬类和/或苯巴比妥。
- 指南实施后,在继续症状触发式给药基础上,启动IV氯胺酮持续输注0.15-0.3 mg/kg/hr,直至谵妄缓解。
- 根据戒断严重程度和激越程度,部分患者在持续输注前给予氯胺酮负荷量0.3 mg/kg。
研究设计与关键结果
- 研究类型为回顾性观察性队列研究,纳入63例患者(指南实施前29例,实施后34例),在学术三级医院ICU进行。
- 氯胺酮组插管几率低于非氯胺酮组(OR 0.14, 95%CI 0.04-0.49, p<0.01)。
- 氯胺酮组ICU停留时间较非氯胺酮组缩短2.83天(95%CI -5.58至-0.089, p=0.043)。
- 氯胺酮组住院时间有缩短趋势但未达统计学显著(减少3.66天, 95%CI -8.40至1.08, p=0.13)。
- 对ICU天数结局,酒精水平和苯二氮䓬总剂量与结局的相关系数显著;对住院天数结局,年龄、天冬氨酸氨基转移酶和丙氨酸氨基转移酶水平与结局的相关系数显著。
证据类型、等级与局限
- 证据类型为回顾性观察性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于ICU中按DSM-V标准诊断的酒精戒断性谵妄患者,在症状触发式苯二氮䓬类和/或苯巴比妥治疗基础上加用氯胺酮持续输注(0.15-0.3 mg/kg/hr,部分患者先给0.3 mg/kg负荷)可能与插管几率降低和ICU停留缩短相关。
- 作者认为,辅助性氯胺酮治疗可能减轻重度酒精戒断中N-甲基-D-天冬氨酸受体刺激所致的神经兴奋性贡献,减少对过度γ-氨基丁酸激动剂介导镇静的需求,并限制相关并发症。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Ketamine offers a plausible mechanism with favorable kinetics in treatment of severe ethanol withdrawal. The purpose of this study is to determine if a treatment guideline using an adjunctive ketamine infusion improves outcomes in patients suffering from severe ethanol withdrawal.
DESIGN: Retrospective observational cohort study.
SETTING: Academic tertiary care hospital.
PATIENTS: Patients admitted to the ICU and diagnosed with delirium tremens by Diagnostic and Statistical Manual of Mental Disorders V criteria.
INTERVENTIONS: Pre and post guideline, all patients were treated in a symptom-triggered fashion with benzodiazepines and/or phenobarbital. Postguideline, standard symptom-triggered dosing continued as preguideline, plus, the patient was initiated on an IV ketamine infusion at 0.15-0.3 mg/kg/hr continuously until delirium resolved. Based upon withdrawal severity and degree of agitation, a ketamine bolus (0.3 mg/kg) was provided prior to continuous infusion in some patients.
MEASUREMENTS AND MAIN RESULTS: A total of 63 patients were included (29 preguideline; 34 postguideline). Patients treated with ketamine were less likely to be intubated (odds ratio, 0.14; p < 0.01; 95% CI, 0.04-0.49) and had a decreased ICU stay by 2.83 days (95% CI, -5.58 to -0.089; p = 0.043). For ICU days outcome, correlation coefficients were significant for alcohol level and total benzodiazepine dosing. For hospital days outcome, correlation coefficients were significant for patient age, aspartate aminotransferase, and alanine aminotransferase level. Regression revealed the use of ketamine was associated with a nonsignificant decrease in hospital stay by 3.66 days (95% CI, -8.40 to 1.08; p = 0.13).
CONCLUSIONS: Mechanistically, adjunctive therapy with ketamine may attenuate the demonstrated neuroexcitatory contribution of N-methyl-D-aspartate receptor stimulation in severe ethanol withdrawal, reduce the need for excessive gamma-aminobutyric acid agonist mediated-sedation, and limit associated morbidity. A ketamine infusion in patients with delirium tremens was associated with reduced gamma-aminobutyric acid agonist requirements, shorter ICU length of stay, lower likelihood of intubation, and a trend toward a shorter hospitalization.
参考来源
- Pizon AF, Lynch MJ, Benedict NJ, et al. Adjunct Ketamine Use in the Management of Severe Ethanol Withdrawal. Crit Care Med. 2018. PMID: 29742583. doi:10.1097/CCM.0000000000003204
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。